Promising Prospect for Chinese Hepatitis B Vaccine Market Driven by the Policies

PRLog (Press Release) - Jul 03, 2009 -
www.shcri.com--On 18th June, 2009, Ministry of Health of PRC launched 6 public health projects, the major contents of one of which were that China planned to vaccinate the hepatitis B vaccines for the non-immune populations below 15 years old in 3 years all over China and further cut down the infection rate and the surface hepatitis B antigen carriers.
In 2009, 23.3 million populations will need vaccinating, accounting for 31% of the populations that should be vaccinated. China is the area of high incidence of hepatitis B and the hepatitis B virus carriers occupy one third in the world. To expand the vaccination scope of the hepatitis B vaccines is the most effective way to control the prevalence of the hepatitis B.
In the previous years, the demands for the hepatitis B vaccines were 36 million person-shares, in which 16 million person-shares were for the planned immunity of the new born and 20 million person-shares were for the needs of vulnerable populations at their own expense. According to the hepatitis B vaccine revaccination plans of Ministry of Health of PRC, there are totally 75 million populations below 15 years old who need revaccination at the completion of 3 years coverage. During 2009 to 2011, the annually new added hepatitis B vaccine demands are 25 million person-shares and the total demands will reach 61 million person-shares.
At present, there are 5 domestic enterprises and two foreign enterprises which supply the hepatitis B vaccines. In 2008, there were totally 116 million (about 38 million person-shares and each person needs 3) which passed through the approval and check, in which Shenzhen Kangtai Biological Products Co., Ltd, Beijing Tiantan Biological Products Corporation Limited, Dalian Hissen Bio-Pharm. Co., Ltd and NCPC GeneTech Biotechnology development Co., Ltd account for 96% of the market shares and are the major suppliers of the hepatitis B vaccines in China.
Shenzhen Kangtai Biological Products Co., Ltd, Beijing Tiantan Biological Products Corporation Limited, Dalian Hissen Bio-Pharm. Co., Ltd and NCPC GeneTech Biotechnology development Co., Ltd are the major suppliers of the hepatitis B vaccines in China and totally accounted for 96% of the market shares in 2008. At present, the total yield capacity of these four enterprises reaches 55 to 60 million person-shares/ year. Beijing Tiantan Biological Products Corporation Limited is reconstructing the plant. By 2010, 20 million person-shares will be newly added to the yield capacity. Hansenule polymorpha hepatitis B vaccines of Hualan Biological Engineering Inc will obtain the approval in the near future, which will supply 15 million person-shares. Besides the supplies of the foreign enterprises, it is believed that the supplies will meet the demands and the price of the hepatitis B vaccines will keep steady. According to the tender price of the hepatitis B vaccines in various regions, it is estimated that the factory price of the vaccines will be as follows: 5 to 6 Yuan (0.73 to 0.88 USD)/person-share of the barm hepatitis B vaccines, 6 to 8 Yuan (0.88-1.17USD)/person-share of CHO cells hepatitis B vaccines, and about 25 Yuan (3.65 USD)/person-share of the hansenule polymorpha hepatitis B vaccines.
Beijing Tiantan Biological Products Corporation Limited is capable of producing 20 million person-shares of the hepatitis B vaccines annually. In 2008, Beijing Tiantan Biological Products Corporation Limited sold 10 million person-shares of the hepatitis B vaccines. Meanwhile, the company is also preparing for the yield capacity expansion and reconstructing the plants. It is predicted that the yield capacity will be expanded to 40 million person-shares/ year by the early of 2010, the largest hepatitis B vaccine production line in China. The production approval of the barm hepatitis B vaccines of Hualan Biological Engineering Inc is being examined by State Food and Drug Administration. It is predicted that the production will be approved within the year and the planned yield capacity will be about 15 million person-shares.

Source: China Research and Intelligence
To get more information, please visit http://shcri.com/reportdetail.asp?id=218
If you'd like to copy or quote this article, please keep the source information
---------------------------------
Contacts:
Eileen Gu
www.shcri.com
Tel: 86-21-5842-6733
Email: eileen@shcri.com